Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects

Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects

Donghoon Shin,1 Younju Lee,1 Deokyoon Jeong,1 Rod Ellis-Pegler2 1Samsung Bioepis Co. Ltd, Incheon, Republic of Korea; 2Auckland Clinical Studies, Ltd., Auckland, New Zealand Purpose: The objective of this study was to demonstrate comparable pharmacokinetic (PK), safety, and tolerability parameters...

Full description

Bibliographic Details
Main Authors:	Shin D, Lee Y, Jeong D, Ellis-Pegler R
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	Drug Design, Development and Therapy
Subjects:	bioequivalence rheumatoid arthritis clinical trial safety TNF-alpha inhibitor
Online Access:	https://www.dovepress.com/comparative-pharmacokinetics-of-an-adalimumab-biosimilar-sb5-administe-peer-reviewed-article-DDDT

Similar Items

Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects
by: Shin D, et al.
Published: (2020-01-01)

Comparison of drug delivery with autoinjector versus manual prefilled syringe and between three different autoinjector devices administered in pig thigh
by: Hill RL, et al.
Published: (2016-08-01)

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
by: Stauffer VL, et al.
Published: (2018-09-01)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021-04-01)

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis
by: Josef S. Smolen, et al.
Published: (2020-08-01)

Effect of TNF-α Blockade in Gingival Crevicular Fluid on Periodontal Condition of Patients with Rheumatoid Arthritis
by: Zeinab Kadkhoda, et al.
Published: (2016-09-01)

Prefilled syringes
by: 8096 British Standards Institution

Adalimumab Induced Systemic Lupus Erythematosus
by: Songül Çildağ, et al.
Published: (2012-03-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
by: Iannone F, et al.
Published: (2022-06-01)

A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza®) in Healthy Male Subjects
by: Gang Mai, et al.
Published: (2021-01-01)

Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis
by: Jaime A Pachon, et al.
Published: (2014-12-01)

Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up
by: Jing-Wen Chen, et al.
Published: (2022-08-01)

Nailfold Videocapillaroscopy in Patients with Rheumatoid Arthritis and Psoriatic Arthropathy on ANTI-TNF-ALPHA Therapy
by: Daniela Anghel, et al.
Published: (2023-06-01)

Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: A Review
by: Tornero Molina J, et al.
Published: (2021-03-01)

Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA
by: Justyna Roszkiewicz, et al.
Published: (2020-08-01)

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
by: Matsumoto T, et al.
Published: (2021-02-01)

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
by: B. Miguel‐Lillo, et al.
Published: (2023-12-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Treatment of granulomatous rosacea with adalimumab
by: Ryan C. Saal, BS, et al.
Published: (2023-10-01)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
by: Maike H. M. Wientjes, et al.
Published: (2021-06-01)

Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants
by: Takuma Yonemura, et al.
Published: (2022-01-01)

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration
by: Bernstein, D, et al.
Published: (2019)

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
by: Demary W, et al.
Published: (2014-08-01)

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis
by: Natalia P. Machado, et al.
Published: (2013-09-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

Switching Patients from Originator to Biosimilar Medications in Rheumatoid Arthritis: Limiting the ‘Nocebo’ Effect
by: Biogen
Published: (2017-08-01)

Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report
by: Omran NE, et al.
Published: (2018-04-01)

Insulin biosimilars in clinical practice
by: A. F. Verbovoy, et al.
Published: (2022-01-01)

First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
by: E L Luchichina, et al.
Published: (2008-10-01)

Maackia amurensis seed lectin (MASL) ameliorates articular cartilage destruction and increases movement velocity of mice with TNFα induced rheumatoid arthritis
by: Kelly L. Hamilton, et al.
Published: (2022-12-01)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
by: Rianne Brouwer, et al.
Published: (2022-12-01)

A Budget impact analysis of adalimumab biosimilar: the Italian context
by: Roberto Ravasio, et al.
Published: (2019-05-01)

Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis
by: Ahmed M Bawazeer, et al.
Published: (2011-01-01)

Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
by: Natalia Kirsten, et al.
Published: (2022-09-01)

Prefilled syringes for intravitreal drug delivery
by: Sassalos TM, et al.
Published: (2019-04-01)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
by: Roy M. Fleischmann, et al.
Published: (2021-09-01)

Self-Administration of Mepolizumab Liquid Using a Single-Use Prefilled Autoinjector
by: Chapman, K, et al.
Published: (2019)